Domperidone and metoclopramide (Formulary)

TAM (Treatments and Medicines) NHS Highland
NHS Highland

DOMPERIDONE

Therapy notes

MHRA advice: Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents (December 2019) (www.gov.uk).
MHRA advice: Apomorphine with domperidone: minimising risk of cardiac side effects (April 2016) (www.gov.uk).
MHRA advice: Risk of cardiac side-effects (December 2014) (www.gov.uk).
MHRA advice: Domperidone: no longer available without prescription (December 2014) (www.gov.uk).

Formulation and dosage details

Formulation:

Tablets 10mg

Dosage:

By mouth, 10mg up to 3 times daily for up to 1 week.

Formulation and dosage details

Formulation:

Suspension 5mg/5mL

Dosage:

By mouth, 10mg up to 3 times daily for up to 1 week.

METOCLOPRAMIDE

Therapy notes

MHRA advice: Metoclopramide: risk of neurological adverse effects (December 2014) (www.gov.uk).

  • Metoclopramide is a prokinetic. It is contra-indicated in gastro-intestinal obstruction, perforation or haemorrhage. Avoid where haematemesis or melaena are present.
  • Caution in Parkinson’s disease.

Formulation and dosage details

Formulation:

Tablets 10mg

Dosage:

10mg up to 3 times daily for up to 5 days. 5mg in young adults 15 to 19 years, body weight under 60kg.

Formulation and dosage details

Formulation:

Oral solution 5mg/5mL

Dosage:

By mouth, 10mg up to 3 times daily for up to 5 days.

Formulation and dosage details

Formulation:

Injection 10mg/2mL

Editorial Information

Document Id: F084